Zobrazeno 1 - 10
of 10
pro vyhledávání: '"T. A. Kumova"'
Autor:
I. N. Medvedev, A. P. Savchenko, S. Yu. Zavalishina, E. G. Krasnova, T. A. Kumova, O. V. Gamolina, I. A. Skoryakina, T. S. Fadeeva
Publikováno v:
Российский кардиологический журнал, Vol 0, Iss 5, Pp 42-45 (2009)
Externí odkaz:
https://doaj.org/article/4949e01bee064bacabce48534b5eb3b4
Publikováno v:
Российский кардиологический журнал, Vol 0, Iss 2, Pp 43-46 (2008)
The study aimed at identifying rapid methods of platelet (PL) hemostasis normalization in patients with arterial hypertension (AH) and metabolic syndrome (MS). Three-month therapy course, including hypocaloric diet, dosed physical exercise, pioglar a
Externí odkaz:
https://doaj.org/article/56e302c4dad54e0eb7c007e2775d6187
Autor:
I. N. Medvedev, T. A. Kumova
Publikováno v:
Российский кардиологический журнал, Vol 0, Iss 4, Pp 52-56 (2007)
The authors compared platelet hemostasis effects for two angiotensin receptor blockers, valsartan and eprosartan, in patients with arterial hypertension (AH) and metabolic syndrome (MS). For 16 weeks, 34 patients received valsartan, and 32 - eprosart
Externí odkaz:
https://doaj.org/article/68f08756d3b14f9a9ba235294da6d87e
Autor:
I. N. Medvedev, T. A. Kumova
Publikováno v:
Российский кардиологический журнал, Vol 0, Iss 3, Pp 66-69 (2007)
То assess angiotensin II receptor blocker effects on platelet aggregation in arterial hypertension (AH) and metabolic syndrome (MS), 34 patients were administered valsartanfor 16 weeks. The dynamics of anthropometry parameters, blood lipids, plasma
Externí odkaz:
https://doaj.org/article/530619bf0e5145ef830ab2bce055315b
Publikováno v:
Российский кардиологический журнал, Vol 0, Iss 4, Pp 82-84 (2009)
Externí odkaz:
https://doaj.org/article/1599193d3a044c79aa4246365a297e33
Autor:
I. N. Medvedev, T. A. Kumova
Publikováno v:
Российский кардиологический журнал, Vol 0, Iss 5, Pp 53-55 (2008)
To assess the angiotensin II blocker effects on platelet (PL) aggregation in patients with arterial hypertension (AH) and metabolic syndrome (MS). In total, 35 patients received losartan for 16 weeks. Dynamics of plasma and PL lipid peroxidation, blo
Externí odkaz:
https://doaj.org/article/e6e77a0b723645e08f7aa94fe6b7e560
Autor:
I. N. Medvedev, T. A. Kumova
Publikováno v:
Российский кардиологический журнал, Vol 0, Iss 1, Pp 40-42 (2008)
Aim: To study therapeutic effects of eprosartan on intravascular platelet activity in patients with arterial hypertension (AH) and metabolic syndrome (MS). Material and methods: In total, 32 participants received eprosartan (600 mg/d) for 4 months. D
Externí odkaz:
https://doaj.org/article/4c34b509f8b8449dbef94e90707b26c7
Autor:
I. N. Medvedev, T. A. Kumova
Publikováno v:
Российский кардиологический журнал, Vol 0, Iss 5, Pp 97-99 (2007)
Externí odkaz:
https://doaj.org/article/e9863cb35b594de8ba6fec955417bc41
Publikováno v:
Voenno-meditsinskii zhurnal. 331(9)
Hypertension is the main disease in Russian Federation--its frequency is 39.2% in men and 41.1% in women. In recent years course of a disease is accompanied by the metabolic derangements which form the metabolic syndrome. In the basis of pathogenesis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3589acc7599fe8322849631c3aeba0cd
https://pubmed.ncbi.nlm.nih.gov/21254528
https://pubmed.ncbi.nlm.nih.gov/21254528
Publikováno v:
Klinicheskaia meditsina. 86(1)
The aim of the study was to evaluate therapeutic effects of losartan on intravascular thrombocyte activity (ITA) in patients suffering from arterial hypertension with metabolic syndrome (MS). The subjects of the study were 35 patients administered lo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::88b4b309cf2fae68d5904a6a8a64b286
https://pubmed.ncbi.nlm.nih.gov/18326282
https://pubmed.ncbi.nlm.nih.gov/18326282